KKR to Acquire Biosynth Carbosynth from Munich-Based Amira

KKR & Co. is acquiring Biosynth Carbosynth, a company that researches, develops and manufactures drugs based in the U.K.

Chief Executive Officer Urs Spitz partnered with Armira Beteiligungen GmbH, a Munich-based firm, in 2014, before merging with Carbosynth Ltd. five years later. The top executive and senior managers will keep a “significant ownership stake” and continue leading the company, KKR said in a press release.

The details of the transaction, which is subject to approval from regulators, were not disclosed. KKR, a $429 billion alternative-asset manager, is funding the acquisition through its Health Care Strategic Growth strategy.

KKR ...